#	Pagina
attuale pagina	/open-h2020/projects/222521/index.html

Opendata, web and dolomites

SHIGETECVAX SIGNED

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Total Cost €

EC-Contrib. €

Partnership

Views

SHIGETECVAX project word cloud

Explore the words cloud of the SHIGETECVAX project. It provides you a very rough idea of what is the project "SHIGETECVAX" about.

live ing mucosal detoxified designed vaccination bangladesh toxin critical shigella populations surface caused material attempts radically almost advancing immunity huge cell complementary induce shigellosis disruption sero multiple shigetec epidemiology costly antigen protection burden gut immunogenicity antibodies vaccines human elimination rational invasion additional manufacture although shared protecting lmics infections invasiveness pathogen enteric efforts lps too closely disease trial reactogenic attenuated natural recognition blocking endemic immune neutralizing advantage doses reduce administration candidates vaccine adults diarrhoea etec virulence serotypes expertise molecular entails possibly safer antigens safety immunodominant oral failed clinical first generations pathogens solution pillars

Project "SHIGETECVAX" data sheet

The following table provides information about the project.

Coordinator	EUROPEAN VACCINE INITIATIVE EWIV Organization address address: VOSSSTRASSE 2 GEB 4040 city: HEIDELBERG postcode: 69115 website: http://www.euvaccine.eu/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Total cost	0 €
EC max contribution	8˙603˙989 € (0%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Two-Stage-RTD
Funding Scheme	RIA-LS
Starting year	2019
Duration (year-month-day)	from 2019-09-01 to 2024-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	EUROPEAN VACCINE INITIATIVE EWIV EUROPEAN VACCINE INITIATIVE EWIV Organization address address: VOSSSTRASSE 2 GEB 4040 city: HEIDELBERG postcode: 69115 website: http://www.euvaccine.eu/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HEIDELBERG)	coordinator	359˙755.00
2	EVELIQURE BIOTECHNOLOGIES GMBH EVELIQURE BIOTECHNOLOGIES GMBH Organization address address: KARL-FARKAS-GASSE 22 city: WIEN postcode: 1030 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	participant	5˙024˙401.00
3	INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH Organization address address: SHAHEED TAJUDDIN AHMED SHARANI 68 city: DHAKA postcode: 1212 website: www.icddrb.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BD (DHAKA)	participant	1˙924˙713.00
4	GOETEBORGS UNIVERSITET GOETEBORGS UNIVERSITET Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 website: www.gu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOETEBORG)	participant	749˙842.00
5	PATH PATH Organization address address: 2201 WESTLAKE AVENUE, SUITE 200 city: SEATTLE postcode: 98121 2767 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (SEATTLE)	participant	545˙277.00

Map

Project objective

Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SHIGETECVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SHIGETECVAX" are provided by the European Opendata Portal: CORDIS opendata.